Seven-membered
nitrogen heterocycles have a strong influence in
drug discovery due to their inherent 3D character, which allows the
ability to explore a vast conformational space with a biological target.
Notably, the privileged 1,4-benzodiazepine scaffold is dominant in
treating the central nervous system due to its binding affinity with
the GABAA receptor. Herein, we report a protocol for the
transformation of azidoquinones to p-quinone fused
5-substituted-1,4-benzodiazepines (p-QBZDs) from
InCl3-catalyzed intermolecular tandem cycloannulation of
azidoquinones with amines and aldehydes. Detailed mechanistic studies
reveal that the EDA complex between azidoquinones and InCl3 is crucial in determining the reaction pathway. In the absence of
EDA complex formation, the reaction proceeds via the intermediacy
of 2,3-bridged-2H-azirine followed by regiospecific
addition of an amine to CN/ring opening/cyclization to deliver p-QBZD with 1,2-azide-nitrogen migration. In the case of
EDA complex formation, the reaction proceeds through regioselective
aza-Michael addition/nitrene insertion with aldehyde and subsequent
cyclization to deliver p-QBZD and p-quinone fused imidazole as a secondary product without 1,2-azide-nitrogen
migration. This protocol provides straightforward access to redox-active
quinone embedded 5-substituted-1,4-benzodiazepines from azidoquinones
with diverse substrate scopes that would find potential applications
in medicinal chemistry and drug discovery.